Cadila Healthcare Limited

Ramesh Chandra Singh

Shri Prakash Dhar Dwivedi

Jigar Mukundbhai Raval

Vikas Patel

Shriprakash Dhar Dwivedi

Pranav Jitendra Gangwar

Sanjay Jagdish Desai

Mukul Hariprasad Sharma

Daya Ram Pal

Jagdish Maganlal Patel

Vishwadeepak Rama Pati Tripathi

Rajendra Gokalbhai Chavda

Dharmendra Arvindbhai Darji

Amar Rajendra Desai

Shirprakash Dhar Dwivedi

Jigar Mukundhai Raval

Vishwadeepak Rama Patil Tripathi

Sachin Ashokrao Patil

The present invention provides pyrroles having hypolipidemic hypocholesteremic activities. The invention provides saroglitazar and its pharmaceutically acceptable salts, hydrates, solvates, polymorphs or intermediates thereof. The invention also provides a process for the preparation of saroglitazar. The invention further provides intermediates as well process for preparation thereof.

Process for preparation of pyrroles having hypolipidemic hypocholesteremic activities

The present invention relates to compositions comprising saroglitazar magnesium wherein the saroglitazar magnesium has a purity of greater than or equal to 99% by weight, and dimer compound of Formula (IV) present in an amount relative to saroglitazar magnesium less than about 0.3% by weight by area percentage of HPLC. The present invention also related to the process for the preparation thereof and pharmaceutical compositions comprising the same.

Pyrrole compound, compositions and process for preparation thereof

The present invention relates to an improved process for the preparation of pyrroles derivatives having hypolipidemic and hypocholesteremic activities. In particular, the invention relates to an improved process for the preparation of 2-ethoxy-3-(4-(2-(2-methyl-5-(4-(methylthio)phenyl)-1H-pyrrol-1-yl)ethoxy)phenyl)propanoate and its pharmaceutically acceptable salts, hydrates, solvates, polymorphs or intermediates thereof. The invention also relates to an improved process for the preparation of mesylate compound (A1).

Process for the preparation of saroglitazar pharmaceutical salts

The present invention relates to Saroglitazar free acid of Formula (IA) or its pharmaceutically acceptable salts, pharmaceutically acceptable solvates, pharmaceutically acceptable esters, stereoisomers, tautomers, analogs and derivatives thereof. The present invention also provides an amorphous form of saroglitazar free acid and processes of preparation thereof. The present invention also provides pharmaceutical composition comprising an amorphous form saroglitazar magnesium. 

Polymorphic form of pyrrole derivative and intermediate thereof

The present invention relates to an amorphous form of vilazodone hydrochloride and process for the preparation of amorphous form of vilazodone hydrochloride. The invention also relates to pharmaceutical compositions that include a therapeutically effective amount of the amorphous form of vilazodone hydrochloride and use of said compositions for the treatment of major depressive disorder (MDD).

Amorphous form of vilazodone hydrochloride and process for its preparation

The present invention discloses process for preparing benzisothiazol-3-yl-piperazin-1-yl-methyl-cyclohexylmethanisoindol-1,3-dione and intermediates thereof.

Process for preparing benzisothiazol-3-yl-piperazin-1-yl-methyl-cyclo hexylmethanisoindol-1,3-dione and its intermediates

The present invention provides crystalline form of intermediates of Formula 2A,  The present invention also provides process for the preparation of dabigatran etexilate mesylate; polymorph of intermediates thereof; particularly processes for the preparation of crystalline form of intermediates. The present invention also relates to the use of crystalline intermediates for the preparation of dabigatran etexilate mesylate.

Growing community of inventors

Gujarat, India

Ramesh Chandra Singh